Ocuphire Pharma Results slide image

Ocuphire Pharma Results

AAO-Preferred Practice Pattern Reveals High Unmet Need in Mild, Moderate, and Severe NPDR Patients Unmet Need Remains High in Mild, Moderate and Severe NPDR Patients Severity of Retinopathy Normal or minimal NPDR Mild NPDR Moderate NPDR Severe NPDR Non-high-risk PDR High-risk PDR Management Recommendations for Patients with Diabetes Presence of Macular Panretinal Photocoagulation (Scatter) Laser Focal and/or Grid Laser* Edema No No NCI-DME CI-DME+ No NCI-DME CI-DME+ No NCI-DME CI-DME+ No NCI-DME CI-DME+ No NCI-DME CI-DME+ Follow-up (Months) 12 12 3-6 1* 6-12+ 3-6 1* 3-4 2-4 7 1* 3-4 2-4 1* 2-4 2-4 1* No No No No No No No Sometimes Sometimes Sometimes Sometimes Sometimes Sometimes Recommended Recommended Recommended No No Sometimes Rarely No Sometimes Rarely No Sometimes Rarely No Sometimes Sometimes No Sometimes Sometimes Intravitreal Anti- VEGF Therapy No No No Usually No Rarely Usually Sometimes Sometimes Usually Sometimes Sometimes Usually Sometimes ¹,2 Sometimes Usually Ocuphire Source: Diabetic Retinopathy Preferred Practice Pattern - AAO 2019; LTFU: Lost To Follow-up; IVT: Intravitreal Injections; PRP: Panretinal Photocoagulation PHARMA An oral option for DR strengthens treatment options across all stages Physicians have limited non-invasive treatment options 23
View entire presentation